4th Quarter - Report
FOLEY HOAG LLP for WAVE LIFE SCIENCES
Firm
Client
Income
$15,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
-Implementation of the Orphan Drug Act of 1938 (Pub. L. No. 97-414) and orphan drug development -Federal funding and regulation of innovative genetic technologies - FDA User Fee Reauthorization Act of 2022, P.L. 117-180, reauthorization of FDA user fees, and Consolidated Appropriations Act, FY2023, P.L. 117-328
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL KIM | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.